« Return to News | CROs/Service Providers

United Drug to acquire pharmacovigilance, market access companies

Tuesday, August 28, 2012 12:21 PM

United Drug, an international provider of healthcare services, will acquire North Carolina-based Drug Safety Alliance for a total of up to $28 million, and North Carolina-based Synopia RX for up to $12 million.

DSA employs 94 people and provides safety and risk management services supporting pharmaceutical, biotech, medical device, animal and consumer health organizations, including detection, assessment, analysis and reporting of adverse drug reactions.

United Drug said DSA complements its U.S. medical information business, Alliance, and will allow for an integrated call center and case processing pharmacovigilance service. Both DSA and Alliance will be part of United Drug’s sales, marketing & medical division.

Synopia provides market access services to pharmaceutical and biotech manufacturers in the U.S., to accelerate the access and positioning of medicines in the payer market. Services include market research, payer strategy development and account management. Synopia also will be part of United Drug’s sales, marketing & medical division.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.